Movfor 200 mg contains Molnupiravir, an oral antiviral drug developed for the treatment of COVID-19. It is used in mild to moderate cases of COVID-19 in adults who are at high risk of progression to severe disease. Movfor helps in reducing viral load, speeding up recovery, and lowering the chances of hospitalization when started early in the course of infection.

Mechanism of action:
Molnupiravir is a prodrug that, once inside the body, is converted into its active form (N-hydroxycytidine). This compound is incorporated into the viral RNA during replication. By introducing errors into the viral genetic material, it causes “error catastrophe,” meaning the virus cannot replicate correctly. This halts further multiplication of the SARS-CoV-2 virus.

Uses:

• Treatment of mild to moderate COVID-19 in adults.

• Specifically recommended for patients with risk factors like old age, diabetes, hypertension, obesity, or chronic lung/heart disease.

• Used only when alternative treatments are not suitable or available.

Adverse effects:
Common side effects include headache, dizziness, diarrhea, and nausea. Some patients may experience fatigue or mild skin rash. Serious adverse effects are rare but may include allergic reactions or worsening of liver function. Molnupiravir is not recommended during pregnancy due to potential risk of harm to the unborn baby, and contraception is advised during and after treatment for a short period.